Serplulimab
Showing 1 - 25 of 43
Gastric Cancer Trial in Xi'an (dietary supplement, biological, drug)
Recruiting
- Gastric Cancer
- Taurine
- +3 more
-
Xi'an, Shaanxi, ChinaTang-Du Hospital
Nov 7, 2023
Gastric Cancer Trial in Shanghai (Serplulimab, Trastuzuma, Chemotherapy)
Recruiting
- Gastric Cancer
- Serplulimab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 27, 2023
Advanced Solid Tumors With Neuroendocrine Differentiation Trial (surufatinib?serplulimab)
Not yet recruiting
- Advanced Solid Tumors With Neuroendocrine Differentiation
- (no location specified)
Nov 27, 2023
NSCLC, Neoadjuvant Therapy Trial in Hangzhou (Serplulimab and neoadjuvant therapy, surgical resection of lung cancer)
Recruiting
- NSCLC
- Neoadjuvant Therapy
- Serplulimab and neoadjuvant therapy
- surgical resection of lung cancer
-
Hangzhou, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
May 22, 2023
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) Trial in Tianjin (Serplulimab+Paclitaxel+Apatinib,
Recruiting
- Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jul 5, 2023
Small Cell Lung Cancer Trial in Fuzhou (Surufatinib,Serplulimab,Etoposide,Carboplatin)
Not yet recruiting
- Small Cell Lung Cancer
-
Fuzhou, Fujian, ChinaFujian Cancer Hospital
May 20, 2023
Serplulimab,Gastric Cancer, Adjuvant Therapy Trial in Shanghai (Serplulimab, Docetaxel, S1)
Recruiting
- Serplulimab,Gastric Cancer, Adjuvant Therapy
- Serplulimab
- +2 more
-
Shanghai, ChinaZhang Zizhen
Mar 3, 2023
Serplulimab in 2L and Above Treatment of Cervical Cancer
Recruiting
- Cervical Cancer
- Serplulimab
-
Jinan, Shandong, ChinaQilu Hospital of Shandong University
May 30, 2023
Small-cell Lung Cancer Trial in Guangzhou (Serplulimab)
Recruiting
- Small-cell Lung Cancer
- Serplulimab
-
Guangzhou, Guangdong, ChinaGuangdong Provincial Perople's Hospital
Jul 20, 2023
Locally Advanced Pancreatic Cancer Trial in Guangzhou (Sulfatinib, Serplulimab, Albumin-paclitaxel)
Not yet recruiting
- Locally Advanced Pancreatic Cancer
- Sulfatinib
- +3 more
-
Guangzhou, Guangdong, ChinaFirst Affiliated Hospital, Sun Yat-Sen University
Aug 10, 2023
Gastroesophageal Junction Adenocarcinoma Trial in Beijing (Serplulimab)
Recruiting
- Gastroesophageal Junction Adenocarcinoma
- Serplulimab
-
Beijing, ChinaPeking Union Medical College Hospital
Jun 15, 2023
Unresectable Lung Non-Small Cell Carcinoma Trial (serplulimab plus chemo as conversion treatment)
Not yet recruiting
- Unresectable Lung Non-Small Cell Carcinoma
- serplulimab plus chemotherapy as conversion treatment
- (no location specified)
Apr 27, 2023
First-Line Serplulimab Plus Chemotherapy in Treatment of
Not yet recruiting
- Lung Cancer
- Serplulimab plus chemotherapy
- (no location specified)
May 16, 2023
Colorectal Cancer Trial in Shanghai (serplulimab, Fruquintinib)
Not yet recruiting
- Colorectal Cancer
- serplulimab
- Fruquintinib
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 13, 2023
Colorectal Cancer, Liver Metastases Trial in Hangzhou (Serplulimab+Regorafenib, Hepatic Artery Bicarbonate Infusion)
Not yet recruiting
- Colorectal Cancer
- Liver Metastases
- Serplulimab+Regorafenib
- Hepatic Artery Bicarbonate Infusion
-
Hangzhou, Zhejiang, Chinathe Second Affiliated Hospital of Medical College of Zhejiang Un
Jun 7, 2023
First-line Treatment of Non-clear Renal Cell Carcinoma Trial (Fruquintinib combined with Serplulimab)
Not yet recruiting
- First-line Treatment of Non-clear Renal Cell Carcinoma
- Fruquintinib combined with Serplulimab
- (no location specified)
Apr 16, 2023
Neuroendocrine Carcinoma Trial in Wuhan (Surufatinib and Serplulimab)
Not yet recruiting
- Neuroendocrine Carcinoma
- Surufatinib and Serplulimab
-
Wuhan, Hubei, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong
Feb 18, 2023
NSCLC, Stage II-IIIA, Immunotherapy Trial in Shanghai (Serplulimab and Chemotherapy)
Recruiting
- Non-small Cell Lung Cancer
- +3 more
- Serplulimab and Chemotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 27, 2023
NSCLC Stage II, Bevacizumab, Immunotherapy Trial in Guangzhou (Serplulimab combined with bevacizumab and first-line chemo)
Not yet recruiting
- Non-small Cell Lung Cancer Stage II
- +3 more
- Serplulimab combined with bevacizumab and first-line chemotherapy
-
Guangzhou, Guangdong, ChinaLikun Chen
Apr 10, 2023
Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)
Not yet recruiting
- Lung Adenocarcinoma
- +3 more
- Serplulimab and Bevacizumab injection
- (no location specified)
Dec 21, 2022
Unresectable Colon Cancer Peritoneal Metastases, PMMR/Ras/BRAF Wild-type Trial in Huzhou (Serplulimab Combined With FOLFIRI and
Recruiting
- Unresectable Colon Cancer Peritoneal Metastases
- PMMR/Ras/BRAF Wild-type
- Serplulimab Combined With FOLFIRI and Bevacizumab
-
Huzhou, Zhejiang, ChinaChangxing County People's Hospital
Feb 14, 2023
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair Trial in China (S1,
Not yet recruiting
- Adenocarcinoma of the Stomach
- +2 more
- S1
- +3 more
-
Hangzhou, Zhejiang, China
- +4 more
May 23, 2023
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Hangzhou (Serplulimab, Albumin paclitaxel, carboplatin AUC=5,
Recruiting
- Esophageal Squamous Cell Carcinoma
- Neoadjuvant Therapy
- Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy
- Esophagectomy
-
Hangzhou, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 20, 2022
Nasopharyngeal Carcinoma by AJCC V8 Stage Trial in Guanzhou (HLX07, HLX10, )
Not yet recruiting
- Nasopharyngeal Carcinoma by AJCC V8 Stage
- HLX07
- +3 more
-
Guanzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 23, 2022